Chlamydia Therapies
Chlamydia Market

Chlamydia 


Chlamydial infection, caused by Chlamydia trachomatis, is the most common bacterial sexually transmitted infection (STI). Age is a strong predictor of risk for chlamydial infections, with the highest infection rates in women occurring during ages 15–24 years. As most individuals with the infection are asymptomatic, it is often left untreated, increasing the risk of transmission and serious health consequences in both sexes.


Chlamydia Epidemiology Segmentation in the 7MM


  • Diagnosed Incident Cases of Chlamydia
  • Gender-specific Cases of Chlamydia
  • Symptom-specific Cases of Chlamydia
  • Age-specific Cases of Chlamydia


Chlamydia Epidemiological Insights Observed in the 7MM (2021)


  • The total diagnosed incident cases of Chlamydia in the 7MM were found to be 3.4 million in the year 2021.
  • The total diagnosed incident cases of Chlamydia in the US were observed to be 1.9 million in the year 2021.
  • The total diagnosed incident cases of Chlamydia in Germany were estimated to be 446k.


Chlamydia Market Insight


The market size of Chlamydia in the 7MM was found to be USD 59.5 million in 2021.  


Chlamydia Emerging Therapies


The emerging drugs in the Chlamydia market are

  • EVO100
  • Chlamydia infection blockers (CIBs)
  • VPI-201
  • Salmonella-Based Vaccine


Chlamydia Key Players 


The key players working in the Chlamydia market are


  • Evofem Biosciences
  • QureTechBio
  • Vault Pharma
  • Aeterna Zentaris, and several others